TSUKASAKI Kunihiro

ツカサキクニヒロ | TSUKASAKI Kunihiro

Affiliation and department：
Job title： Professor
Research theme for competitive and other funds (2)：

開発費大江班
AMED塚崎班

Papers (41)：

Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, Morishima S, Tsukasaki K, Kawamata T, Ono T, et al. An Open-Label, Single-Arm, Phase 2 Trial of Valemetostat in Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma. Blood. 2023. 141(10):1159-1168
Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, Yokoyama M, Tsukasaki K, Kuroda J, Ando J, et al. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. Haematologica. 2023. 108(3):811-821
塚崎邦弘. 塚崎邦弘,再発・難治性びまん性大細胞型B細胞リンパ腫(R/RDLBCL)の治療と今後の展望. Pharma Medica,. 2023. Vol.40 No1:53-57
Maruyama D, Iida S, Machida R, Kusumoto S, Fukuhara N, Yamauchi N, Miyazaki K, Yoshimitsu M, Kuroda J, Tsukamoto N, et al. Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105). Cancer Sci. 2022. 113(9):3267-3270
塚崎邦弘. CD30陽性PTCLに対するbrentuximab vedotin-CHP療法のランダム化第III相試験(ECHELON-2)の5年フォローアップデータ. 血液内科. 2022. 85(4):586-592

ｍore...

MISC (1)：

Utsunomiya A, Izutsu K, Jo T, Yoshida S, Tsukasaki K, Ando K, Choi I, Imaizumi Y, Kato K, Kurosawa M, et al. Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma: Phase IIb results. Cancer Science. 2022

Books (9)：

Adult T-cell leukaemia/lymphoma, in Haematolymphoid Tumours (5th ed.), WHO Classification oh Tumours
online. IARC publications 2022
,Adult T-cell leukaemia/lymphoma, in Haematolymphoid Tumours (5th ed.), WHO Classification oh Tumours
online. IARC publications 2022
「EBM 血液疾患の治療2023-2024(金倉譲監修) 2.ATLに対する造血幹細胞移植」
(株)中外医学社 2022
成人T細胞白血病・リンパ腫,菌状息肉症,その他のリンパ増殖性疾患「内科学第12版朝倉」
朝倉書店 2022
成人T細胞白血病・リンパ腫,菌状息肉症,その他のリンパ増殖性疾患内科学第12版朝倉
朝倉書店 2022

ｍore...

Lectures and oral presentations (23)：

Oral Azacytidine in Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: Final Analysis of the Oracle Phase III Study.
(64th ASH Annual Meeting and Exposition 2022)
Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study).
(64th ASH Annual Meeting and Exposition. 2022)
Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma.
(64th ASH Annual Meeting and Exposition 2022)
P-IIb study of oral HDAC inhibitor HBI-8000 in relapsed or refractory adult T-cell leukemia/lymphoma,
(2022)
Characteristics of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma - a supplementary analysis of JCOG0601.
(EHA 2022 2022)

ｍore...

Education (1)：

1978 - 1984 Nagasaki University Faculty of Medicine

Professional career (1)：

医学博士 (長崎大学)

Committee career (4)：

2022/06 - 現在日本リンパ網内系学会プログラム委員会
2012/07 - 現在厚生労働省HTLV-1対策推進協議会委員
2021/06 - 2022/06 日本リンパ網内系学会プログラム委員会
2017/04 - 2020/09 日本血液学会プログラム委員会リンパ腫領域委員長

Association Membership(s) (13)：

American Society of Hematology , 長崎医学会 , 日本造血幹細胞移植学会 , 日本血液学会 , 日本臨床腫瘍学会 , 日本癌学会 , 日本検査血液学会 , 日本内科学会 , 日本リンパ網内系学会 , 日本HTLV-1学会 , American Society of Clinical Oncology , 日本皮膚悪性腫瘍学会 , American Society oh Hematology

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page